Compare · ABT vs PRTA
ABT vs PRTA
Side-by-side comparison of Abbott Laboratories (ABT) and Prothena Corporation plc (PRTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PRTA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.63B, about 344.7x PRTA ($460.2M).
- Over the past year, ABT is down 32.0% and PRTA is up 62.8% - PRTA leads by 94.8 points.
- ABT has been more active in the news (6 items in the past 4 weeks vs 3 for PRTA).
- ABT has more recent analyst coverage (25 ratings vs 22 for PRTA).
- Company
- Abbott Laboratories
- Prothena Corporation plc
- Price
- $90.75-0.34%
- $8.58-2.22%
- Market cap
- $158.63B
- $460.2M
- 1M return
- +4.30%
- -17.93%
- 1Y return
- -32.00%
- +62.81%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 3
- Recent ratings
- 25
- 22
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest PRTA
- Large owner Scully William P bought $465,295 worth of Ordinary Shares (50,000 units at $9.31), increasing direct ownership by 6% to 936,000 units (SEC Form 4)
- Large owner Scully William P bought $471,300 worth of Ordinary Shares (50,000 units at $9.43), increasing direct ownership by 6% to 886,000 units (SEC Form 4)
- Large owner Scully William P bought $981,300 worth of Ordinary Shares (100,000 units at $9.81), increasing direct ownership by 14% to 836,000 units (SEC Form 4)
- SEC Form 4 filed by Director Welch Daniel G
- SEC Form 4 filed by Director Selkoe Dennis J.
- SEC Form 4 filed by Director Ekman Lars
- SEC Form 4 filed by Director Dunn William H. Jr.
- SEC Form 4 filed by Director Cooke Shane
- SEC Form 4 filed by Director Collier Richard T
- New insider Scully William P claimed ownership of 868,000 units of Ordinary Shares (SEC Form 3)